pharmaceutical industryBusinessTrump’s FDA Cuts Are Putting Drug Development at RiskBy Caroline HaskinsScienceThe Ozempic Shortage Is OverBy Kate Knibbs and Emily MullinThe Big StoryThe King of Ozempic Is Scared as HellBy Virginia HeffernanScienceRFK Plans to Take on Big Pharma. It’s Easier Said Than DoneBy Emily MullinBusinessMark Cuban’s War on Drug Prices: ‘How Much Fucking Money Do I Need?’By Marah EakinScienceThe Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster DrugBy Kate Knibbs and Emily MullinScienceThe Crackdown on Compounded GLP-1 Meds Has BegunBy Kate KnibbsThe Big StoryAfter Shark Tank, Mark Cuban Just Wants to Break Shit—Especially the Prescription Drug IndustryBy Lauren GoodeScienceThe FDA Just Rejected a Bid for MDMA to Treat PTSDBy Emily MullinScienceIt’s Shockingly Easy to Buy Off-Brand Ozempic Online, Even if You Don’t Need ItBy Kate KnibbsScienceA Pill That Kills Ticks Is a Promising New Weapon Against Lyme DiseaseBy Emily MullinScienceA Study at the Center of the Abortion Pill Battle Was Just RetractedBy Emily MullinScienceA Startup Has Unlocked a Way to Make Cheap InsulinBy Emily MullinScienceA Gel Injected Into the Scrotum Could Be the Next Male ContraceptiveBy Emily MullinThe Big StoryYou Know It’s a Placebo. So Why Does It Still Work?By Tom VanderbiltScienceA Single Infusion of a Gene-Editing Treatment Lowered High CholesterolBy Emily MullinScienceWegovy Slashes the Risk of Heart Attack and Stroke in a Landmark TrialBy Emily MullinScienceThe FDA Approves Weight Loss Drug Zepbound, a Wegovy and Ozempic RivalBy Emily MullinScienceCovid Boosters Can’t Outpace New Mutations. Here’s Why They Still WorkBy Emily MullinScienceOzempic and Wegovy Can Also Protect Your HeartBy Emily MullinScienceThe First Pill for Postpartum Depression Is Almost HereBy Emily MullinScienceThe US Finally Approved an Over-the-Counter Birth Control Pill. Here’s What to KnowBy Emily MullinScienceA One-Time Shot for Type 2 Diabetes? A Biotech Company Is On ItBy Emily MullinScienceAbortion Pill Use Is Surging. Now It’s Under ThreatBy Emily Mullin and Kate KnibbsMore Stories
.jpg)
